Article Title: Novo’s MFN prices to supersede IRA prices for Ozempic, Wegovy, CMS says
Publication Date: Wednesday, 26 November 2025
As reported by Endpoints News on November 26, 2025, new negotiated prices for Novo Nordisk’s GLP-1 drugs under the Inflation Reduction Act (IRA) have given rise to inquiries about their influence on the prices Novo earlier agreed to under its separate “most favored nation” (MFN) agreement.
Key drugs impacted are Ozempic and Wegovy, which are both a part of Novo Nordisk’s expanding portfolio in the GLP-1 drugs sector. The pricing dynamics provoked by the interaction of the IRA and the MFN clause are under intense scrutiny as they bear significant implications for company revenues and long-term stability in the biotech market.
The Centers for Medicare and Medicaid Services (CMS) confirmed that the MFN prices would take precedence over those negotiated under the IRA. This is an important specification given the potential for price conflicts between the two regulatory mechanisms. It demonstrates the unique regulatory challenges faced by companies in their capacity to set prices and maintain revenue within legal frameworks.
The potential impact of the MFN clause on Novo’s financial prospects is considerable. The specific MFN price level is yet to be disclosed, however, if it is significantly lower than the previously agreed-upon IRA prices, it could potentially reduce Novo’s expected revenue from the sales of Ozempic and Wegovy. For industry executives and investors, the unfolding events serve as a reminder of the imperative need for effective scenario planning, risk mitigation tactics, and robust financial forecasting in the highly regulated biotech industry.
In closing, it is crucial that investors and industry stakeholders stay informed about evolving regulatory measures and their impacts on biotech and pharmaceutical economies. Industry Informant continues its dedication to providing high-integrity, timely intelligence, supporting our readership in making informed, strategic decisions in the biotech market landscape.
